252 related articles for article (PubMed ID: 35998020)
61. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract][Full Text] [Related]
62. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
Li X; Wang H; Li T; Wang L; Wu X; Liu J; Xu Y; Wei W
Curr Probl Cancer; 2020 Apr; 44(2):100516. PubMed ID: 31836136
[TBL] [Abstract][Full Text] [Related]
63. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
[TBL] [Abstract][Full Text] [Related]
64. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
65. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
66. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
Chin YM; Shibayama T; Chan HT; Otaki M; Hara F; Kobayashi T; Kobayashi K; Hosonaga M; Fukada I; Inagaki L; Ono M; Ito Y; Takahashi S; Ohno S; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2022 May; 113(5):1808-1820. PubMed ID: 35201661
[TBL] [Abstract][Full Text] [Related]
67. Circulating ctDNA methylation quantification of two DNA methyl transferases in papillary thyroid carcinoma.
Khatami F; Teimoori-Toolabi L; Heshmat R; Nasiri S; Saffar H; Mohammadamoli M; Aghdam MH; Larijani B; Tavangar SM
J Cell Biochem; 2019 Oct; 120(10):17422-17437. PubMed ID: 31127647
[TBL] [Abstract][Full Text] [Related]
68. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
[TBL] [Abstract][Full Text] [Related]
69. Circulating Tumor DNA in Breast Cancer: Current and Future Applications.
Medford AJ; Denault EN; Moy B; Parsons HA; Bardia A
Clin Breast Cancer; 2023 Oct; 23(7):687-692. PubMed ID: 37438196
[TBL] [Abstract][Full Text] [Related]
70. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
71. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
72. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
73. Circulating tumor DNA: from discovery to clinical application in breast cancer.
Xu J; Gao H; Guan X; Meng J; Ding S; Long Q; Yi W
Front Immunol; 2024; 15():1355887. PubMed ID: 38745646
[TBL] [Abstract][Full Text] [Related]
74. Early-Stage Breast Cancer Detection in Breast Milk.
Saura C; Ortiz C; Matito J; Arenas EJ; Suñol A; Martín Á; Córdoba O; Martínez-Sabadell A; García-Ruiz I; Miranda I; Morales-Comas C; Carrasco E; Viaplana C; Peg V; Nuciforo P; Bayó-Puxan N; Gonzalez-Medina A; Miquel JM; Gómez-Rey M; Villacampa G; Arévalo S; Espinosa-Bravo M; Balmaña J; Dienstmann R; Arribas J; Tabernero J; Vivancos A; Sansó M
Cancer Discov; 2023 Oct; 13(10):2180-2191. PubMed ID: 37704212
[TBL] [Abstract][Full Text] [Related]
75. Technical progress in circulating tumor DNA analysis using next generation sequencing.
Bai Y; Wang Z; Liu Z; Liang G; Gu W; Ge Q
Mol Cell Probes; 2020 Feb; 49():101480. PubMed ID: 31711827
[TBL] [Abstract][Full Text] [Related]
76. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
77. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
78. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
79. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
80. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
Shulman DS; Klega K; Imamovic-Tuco A; Clapp A; Nag A; Thorner AR; Van Allen E; Ha G; Lessnick SL; Gorlick R; Janeway KA; Leavey PJ; Mascarenhas L; London WB; Vo KT; Stegmaier K; Hall D; Krailo MD; Barkauskas DA; DuBois SG; Crompton BD
Br J Cancer; 2018 Aug; 119(5):615-621. PubMed ID: 30131550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
